SK Bioscience (KRX: 302440)
Who is buying SK Bioscience?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩4.7bn ($4M) of SK Bioscience, the 66th largest foreign net purchase among 832 KOSPI stocks. Institutions net sold ₩4.2bn ($3M) and retail investors net sold ₩0.6bn ($0M) over the same window. Foreigners were net buyers on 11 of the 20 sessions.
Foreign investors hold 6.11% of SK Bioscience's listed shares (KRX ownership data as of Oct 13, 2026), up from 5.98% twenty sessions earlier and 5.71% a year ago.
The stock closed at ₩36,450 on Oct 13, 2026: -2.28% over 20 sessions, -24.38% year-to-date, -20.67% over one year. The 52-week range is ₩31,800 – ₩61,300.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩36,450 | +₩1.0bn | +₩0.4bn | ₩-1.4bn |
| 2026-10-12 | ₩36,450 | ₩-0.3bn | +₩0.4bn | ₩-0.1bn |
| 2026-10-08 | ₩36,750 | +₩1.2bn | ₩-1.4bn | +₩0.2bn |
| 2026-10-07 | ₩38,000 | +₩0.0bn | ₩-0.3bn | ₩-0.3bn |
| 2026-10-06 | ₩37,250 | +₩0.9bn | ₩-0.0bn | ₩-1.0bn |
| 2026-10-02 | ₩36,500 | ₩-0.4bn | ₩-0.1bn | +₩0.4bn |
| 2026-10-01 | ₩36,800 | +₩1.2bn | ₩-0.2bn | ₩-1.0bn |
| 2026-09-30 | ₩36,100 | +₩0.4bn | ₩-0.2bn | ₩-0.3bn |
| 2026-09-29 | ₩35,900 | ₩-0.5bn | +₩0.0bn | +₩0.5bn |
| 2026-09-28 | ₩36,450 | +₩1.1bn | ₩-0.1bn | ₩-1.0bn |
| 2026-09-23 | ₩35,750 | ₩-0.0bn | ₩-0.4bn | +₩0.4bn |
| 2026-09-22 | ₩35,750 | +₩0.1bn | ₩-0.3bn | +₩0.3bn |
| 2026-09-21 | ₩35,650 | +₩0.2bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-18 | ₩35,150 | ₩-1.6bn | +₩0.2bn | +₩1.5bn |
| 2026-09-17 | ₩36,250 | ₩-0.2bn | ₩-0.3bn | +₩0.4bn |
| 2026-09-16 | ₩36,200 | ₩-0.3bn | ₩-0.1bn | +₩0.5bn |
| 2026-09-15 | ₩36,750 | ₩-0.4bn | ₩-0.9bn | +₩1.3bn |
| 2026-09-14 | ₩37,800 | +₩1.1bn | ₩-0.5bn | ₩-0.5bn |
| 2026-09-11 | ₩37,250 | ₩-0.0bn | ₩-0.4bn | +₩0.4bn |
| 2026-09-10 | ₩38,000 | +₩1.1bn | ₩-0.1bn | ₩-1.0bn |
| 2026-09-09 | ₩37,300 | ₩-0.1bn | +₩0.3bn | ₩-0.2bn |
| 2026-09-08 | ₩36,750 | ₩-0.4bn | ₩-0.0bn | +₩0.5bn |
| 2026-09-07 | ₩37,600 | ₩-0.3bn | +₩0.4bn | ₩-0.1bn |
| 2026-09-04 | ₩37,900 | ₩-0.2bn | +₩0.2bn | +₩0.1bn |
| 2026-09-03 | ₩37,750 | +₩0.8bn | ₩-0.4bn | ₩-0.4bn |
| 2026-09-02 | ₩37,450 | +₩0.5bn | ₩-0.6bn | +₩0.1bn |
| 2026-09-01 | ₩38,350 | +₩0.7bn | ₩-0.3bn | ₩-0.4bn |
| 2026-08-31 | ₩38,400 | ₩-0.1bn | ₩-0.1bn | +₩0.3bn |
| 2026-08-28 | ₩38,950 | +₩0.2bn | +₩0.3bn | ₩-0.5bn |
| 2026-08-27 | ₩38,450 | +₩0.1bn | +₩0.5bn | ₩-0.6bn |
| 2026-08-26 | ₩38,100 | +₩0.6bn | +₩0.1bn | ₩-0.6bn |
| 2026-08-25 | ₩37,550 | ₩-0.7bn | ₩-0.2bn | +₩0.9bn |
| 2026-08-24 | ₩38,300 | +₩0.5bn | ₩-0.1bn | ₩-0.4bn |
| 2026-08-21 | ₩36,500 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-08-20 | ₩37,750 | +₩1.8bn | ₩-1.6bn | ₩-0.1bn |
| 2026-08-19 | ₩35,800 | +₩0.0bn | ₩-0.2bn | +₩0.1bn |
| 2026-08-18 | ₩36,500 | ₩-0.7bn | ₩-0.5bn | +₩1.2bn |
| 2026-08-14 | ₩37,650 | ₩-0.0bn | +₩0.4bn | ₩-0.3bn |
| 2026-08-13 | ₩36,850 | +₩2.3bn | ₩-1.4bn | ₩-0.8bn |
| 2026-08-12 | ₩36,500 | ₩-1.4bn | +₩0.3bn | +₩1.2bn |
| 2026-08-11 | ₩37,500 | +₩0.3bn | +₩0.3bn | ₩-0.5bn |
| 2026-08-10 | ₩37,250 | ₩-0.3bn | ₩-0.0bn | +₩0.4bn |
| 2026-08-07 | ₩36,850 | +₩0.3bn | +₩0.4bn | ₩-0.7bn |
| 2026-08-06 | ₩35,900 | +₩0.6bn | +₩0.5bn | ₩-1.1bn |
| 2026-08-05 | ₩34,600 | ₩-0.6bn | ₩-0.1bn | +₩0.7bn |
| 2026-08-04 | ₩34,650 | +₩0.3bn | +₩0.1bn | ₩-0.4bn |
| 2026-08-03 | ₩34,200 | +₩0.7bn | ₩-0.3bn | ₩-0.3bn |
| 2026-07-31 | ₩33,850 | +₩0.6bn | ₩-0.6bn | ₩-0.0bn |
| 2026-07-30 | ₩33,150 | +₩1.2bn | +₩0.6bn | ₩-1.7bn |
| 2026-07-29 | ₩32,500 | +₩0.7bn | +₩0.3bn | ₩-0.9bn |
| 2026-07-28 | ₩33,800 | ₩-0.4bn | +₩0.6bn | ₩-0.2bn |
| 2026-07-27 | ₩34,850 | +₩0.3bn | +₩0.2bn | ₩-0.5bn |
| 2026-07-24 | ₩34,350 | +₩1.6bn | +₩0.0bn | ₩-1.6bn |
| 2026-07-23 | ₩33,650 | +₩0.0bn | +₩0.3bn | ₩-0.3bn |
| 2026-07-22 | ₩32,750 | ₩-0.3bn | ₩-0.1bn | +₩0.4bn |
| 2026-07-21 | ₩33,000 | ₩-0.5bn | ₩-0.2bn | +₩0.7bn |
| 2026-07-20 | ₩33,950 | ₩-1.0bn | +₩0.3bn | +₩0.7bn |
| 2026-07-16 | ₩35,450 | +₩0.6bn | +₩0.2bn | ₩-0.6bn |
| 2026-07-15 | ₩35,200 | +₩0.2bn | ₩-0.4bn | +₩0.3bn |
| 2026-07-14 | ₩35,000 | ₩-0.0bn | +₩0.4bn | ₩-0.4bn |
| 2026-07-13 | ₩36,300 | +₩0.3bn | +₩0.2bn | ₩-0.5bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩1.0bn | +$1M | +₩0.4bn | ₩-1.4bn |
| 5 days | +₩2.9bn | +$2M | ₩-0.9bn | ₩-2.6bn |
| 20 days | +₩4.7bn | +$4M | ₩-4.2bn | ₩-0.6bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying SK Bioscience stock?
Over the last 5 sessions foreign investors net bought ₩2.9bn ($2M) of SK Bioscience; over 60 sessions they net bought ₩12.8bn ($10M); since Jan 1, 2026 they net sold ₩9.2bn ($7M). Over 20 sessions the stock is the 66th largest foreign net purchase among 832 KOSPI stocks.
How much of SK Bioscience do foreign investors own?
Foreign investors own 6.11% of SK Bioscience's shares as of Oct 13, 2026, versus 5.71% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩4.2bn ($3M) and retail investors net sold ₩0.6bn ($0M) of SK Bioscience. Foreign buying is being met mainly by retail selling.
Is SK Bioscience listed on KOSPI or KOSDAQ?
SK Bioscience (SK바이오사이언스) trades on KOSPI under KRX code 302440 in the Biotech & Pharma group, with a market capitalization of ₩3T ($2.1B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩370bn ($277M) | – | -₩12bn (-$9M) | ₩22bn ($17M) |
| 2024 | ₩268bn ($201M) | -27.60% | -₩138bn (-$104M) | -₩50bn (-$38M) |
| 2025 | ₩651bn ($489M) | +143.50% | -₩124bn (-$93M) | -₩56bn (-$42M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.